Neuropathic Pain Market

Vertex Pharmaceuticals raised its estimate of the United States diabetic peripheral neuropathy (DPN) population from about 2 million to about 2.5 million people on 11 January 2026, and said it expects to complete enrollment in both Phase 3 studies of suzetrigine in DPN by the end of 2026. The neuropathic pain market covers prescription medicines that treat pain arising from damaged or diseased nerves: gabapentinoids, antidepressants, opioids, topical patches and new sodium-channel blockers. Douglas Insights sizes it at USD 7.88 billion in 2025, the product of 46.82 million treated patient-years and an average net drug cost of USD 168.3. Revenue climbs to USD 13.8 billion by 2035, a 5.77% revenue CAGR built from 3.12% patient growth and a 2.57% price-mix gain. The study belongs to our pain management therapeutics work, and each step follows the Douglas Insights research methodology.

Who sells pregabalin, mirogabalin and NaV1.8 blockers into the neuropathic pain market, and how concentrated is it?

Generic makers hold most neuropathic pain value, so concentration is low: Douglas Insights estimates the top three branded holders, Viatris, Daiichi Sankyo and Grünenthal, take 10.4% of the USD 7.88 billion 2025 total. Viatris leads with a 5.4% share, earned through Lyrica (pregabalin) across nerve pain indications.

Viatris reported Lyrica net sales of USD 487.0 million for full-year 2025, against USD 495.4 million in 2024 in its fourth-quarter release of 26 February 2026. Douglas Insights attributes about 87% of that pregabalin brand to neuropathic indications, roughly USD 424 million, with the balance in other indications. The brand slipped 1.7% in a year. Generic pregabalin keeps eroding it.

Daiichi Sankyo sells Tarlige (mirogabalin), an alpha-2-delta ligand, in Japan, and its 2025 shareholder report records Chinese approval of mirogabalin for diabetic peripheral neuropathic pain. Our model gives the brand 3.1% of neuropathic pain value, about USD 244 million, most of it in Japan. Grünenthal reported stable 2025 group revenue of EUR 1.8 billion and named its Qutenza capsaicin patch as a growth product; Douglas Insights puts its neuropathic share at 1.9%, about USD 150 million.

Collegium Pharmaceutical reported Nucynta franchise net revenue of USD 196.3 million for 2025, up 11%, and we allocate about 32% of that tapentadol revenue to nerve pain, a 0.8% share. Vertex Pharmaceuticals has no neuropathic label yet, but more than 500,000 Journavx (suzetrigine) prescriptions were written and filled in 2025 in acute pain, and its payer access reaches about two-thirds of United States covered lives. Lexicon Pharmaceuticals is the sixth name to watch, with pilavapadin heading for Phase 3 in diabetic nerve pain.

Which nerve conditions sit inside the neuropathic pain market, from postherpetic neuralgia to radiculopathy?

Five named conditions carry 86.3% of neuropathic pain drug value in 2025, with diabetic peripheral neuropathy alone at 41.3%, or about USD 3.25 billion. Douglas Insights counts drug sales only; spinal cord stimulators, nerve blocks and physiotherapy sit outside this neuropathic pain total.

Postherpetic neuralgia, the burning pain that persists after shingles, holds 11.8% of value. Chemotherapy-induced peripheral neuropathy takes 9.6% and grows with cancer survivorship. Trigeminal neuralgia is small, at 4.4%, and served mostly by older anticonvulsants. Lumbosacral radiculopathy, nerve-root pain from the lower spine, accounts for 19.2%. Mixed and central conditions, such as post-stroke and spinal cord injury pain, make up the remaining 13.7%.

Device spending is covered separately in the Pain Management Devices Market study, which sizes the stimulator and nerve-block side of nerve pain care. Over-the-counter analgesics also fall outside, because they carry no neuropathic claim; the Acetaminophen Market report tracks that molecule on its own.

Which drug class makes the money in neuropathic pain, gabapentinoids or newer sodium-channel blockers?

Anticonvulsants (gabapentinoids) make the money, with 38.7% of neuropathic pain value, or USD 3.05 billion in 2025, because generic pregabalin and gabapentin are the cheapest daily option. Sodium-channel and novel non-opioid agents grow fastest, at 18.75% a year, from the smallest base of the six classes.

Anticonvulsants rise from USD 3.05 billion to USD 4.56 billion at 4.10% a year; volume keeps climbing while generic prices fall. Antidepressants, chiefly serotonin-norepinephrine reuptake inhibitors (SNRI) such as duloxetine and tricyclic antidepressants (TCA) such as amitriptyline, hold 17.9%, or USD 1.41 billion, because they treat sleep and mood problems alongside nerve pain. Opioids and tapentadol hold 14.6%, USD 1.15 billion, but grow only 1.90% as prescribers cut opioid exposure. Generics still rule.

Topical agents (capsaicin and lidocaine) take 12.8%, USD 1.01 billion, and grow 6.40% because patches avoid the dizziness and sedation of oral drugs in older patients. Other drug classes, including carbamazepine and oxcarbazepine for trigeminal neuralgia, hold 9.7%, USD 764.3 million. Sodium-channel blockers start at 6.3%, USD 496.4 million, and reach USD 2.77 billion by 2035 if suzetrigine and its successors win DPN labels. That 18.75% rate is the fastest in the neuropathic pain market.

Why are diabetic peripheral neuropathy caseloads lifting neuropathic pain demand so steadily?

Three forces add 3.12 points a year to neuropathic pain patient volume, and diabetic nerve damage supplies 1.46 of them. Douglas Insights expects treated patient-years to rise from 46.82 million in 2025 to 63.66 million in 2035, across all five regions.

Diabetes keeps feeding the DPN pool

The National Institute of Neurological Disorders and Stroke states that about 60 to 70 percent of people with diabetes have mild to severe nerve damage, and that more than 20 million people in the United States have some form of peripheral neuropathy. The International Diabetes Federation counts about 589 million adults aged 20 to 79 with diabetes and projects 853 million by 2050. Vertex now targets about 2.5 million DPN patients in the United States alone, a 25% upward revision. Douglas Insights credits diabetes growth with 1.46 points of the volume leg, the largest single contribution in the neuropathic pain model. In our build, each diagnosed DPN patient generates about 0.62 treated patient-years a year, because many patients stop, switch or pause therapy. Raising that persistence ratio by 0.05 would add roughly 2 million patient-years by 2035.

Older patients and cancer survivors

Ageing populations and cancer survivorship add 0.87 points. Postherpetic neuralgia follows a share of shingles cases in older adults, and chemotherapy-induced peripheral neuropathy grows as more patients survive cancer treatment. Together these two conditions hold 21.4% of neuropathic pain value, about USD 1.69 billion in 2025. Recurrent prescriptions matter here, since postherpetic and chemotherapy nerve pain often last for years rather than weeks.

Treatment rates rise in Asia Pacific

Wider diagnosis and treatment in Asia Pacific adds the final 0.79 points. Three in four adults with diabetes live in low- and middle-income countries, according to the International Diabetes Federation, where nerve pain often goes untreated. Mirogabalin approval in China opens a second branded alpha-2-delta option there, beside generic pregabalin. Douglas Insights models Asia Pacific treated patient-years rising 6.4% a year, double the global pace. The region holds 23.6% of 2025 value but contributes 37.0% of the decade value gain, a gap that makes it the most important volume story in neuropathic pain.

Price adds the second leg, 2.57% a year. Generic erosion pulls average cost down, yet the mix moves toward patches and branded sodium-channel blockers. Vertex enrolling both suzetrigine Phase 3 studies by end-2026 is the single biggest swing factor in that price-mix gain. The 1.46, 0.87 and 0.79 point contributions sum to the 3.12% volume leg exactly.

What headwinds slow neuropathic pain prescribing after pregabalin scheduling and generic erosion?

Three headwinds remove 1.47 points a year from the neuropathic pain growth rate, and generic price erosion is the largest at 0.94 points. Without them, the 2035 total would sit near USD 15.9 billion rather than USD 13.8 billion in the base case.

Generic erosion strips 0.94 points from the price leg. Lyrica net sales fell 1.7% between 2024 and 2025, and generic pregabalin and gabapentin sell for a fraction of brand prices in every major market. Duloxetine faces the same pressure. Every new neuropathic pain brand must justify a premium over these daily generics.

Controlled-drug rules remove 0.31 points of volume. The United Kingdom moved pregabalin and gabapentin into Schedule 3 with 28-day prescription validity, and other health systems watch gabapentinoid misuse closely. Prescribers respond with shorter scripts and closer review, which trims refill volume in neuropathic pain.

Trial risk removes 0.22 points. Lexicon’s pilavapadin missed its overall primary endpoint at p=0.11 when the 20 mg arm failed to separate from placebo, a reminder that neuropathic pain trials carry high placebo responses. Slow readouts delay premium launches. That is the drag.

Where does Asia Pacific outpace North America in neuropathic pain spending to 2035?

North America leads neuropathic pain spending with USD 3.45 billion in 2025, 43.8% of the total, while Asia Pacific grows fastest at 8.10% a year. Branded prices and high diagnosis rates explain the North American lead; diabetes caseloads explain Asian growth.

North America climbs to USD 5.73 billion by 2035 at 5.20% a year, helped by early sodium-channel blocker launches. Europe holds USD 1.90 billion, 24.1% of value, and grows 4.30% to USD 2.89 billion; generic substitution and controlled-drug rules keep its rate lowest among large regions. Asia Pacific rises from USD 1.86 billion to USD 4.05 billion, nearly overtaking Europe. Asia sets the pace. Japan prescribes mirogabalin and China opens to new alpha-2-delta brands.

Latin America is worth USD 401.9 million in 2025 and grows 6.20% to USD 733.4 million, with Brazil and Mexico carrying most diabetic nerve pain prescriptions in our model. The Middle East and Africa is the wildcard: USD 267.9 million today, growing 4.09% to USD 399.9 million, where our model assumes low treatment rates for diabetic nerve pain. A faster switch to branded neuropathic pain therapy there would lift its rate well above the model.

Footwear and wound programmes for diabetic feet sit beside this drug spend; the Diabetic Footwear Market study tracks the protective side of the same patient pool.

How much do payers spend per patient-year on neuropathic pain drugs, from generic gabapentin to capsaicin patches?

Payers spend an average USD 168.3 per treated patient-year on neuropathic pain drugs in 2025, net of rebates, rising to USD 216.9 by 2035. Cheap generic gabapentinoids pull the average down; branded patches and new blockers pull it up across every region.

Generics set the floor. Douglas Insights puts realised generic gabapentin and pregabalin therapy at USD 35 to USD 95 per patient-year in most markets. Generic duloxetine sits in a similar USD 40 to USD 120 band. Branded alpha-2-delta therapy in Japan realises about USD 450 to USD 700 a year. Prescription capsaicin patch courses run about USD 1,200 to USD 2,400 a year for patients who need repeat applications.

Branded sodium-channel blockers, if approved for DPN, enter at USD 2,500 to USD 4,500 per patient-year net in our model, priced against opioids rather than generics. Our model prices Asia Pacific neuropathic pain therapy 41% below the global average, which caps that region’s value despite its fast volume growth.

Which pharmacy channel fills neuropathic pain scripts: retail pharmacy, hospital pharmacy or online pharmacy?

Retail pharmacy fills 64.2% of neuropathic pain drug value in 2025, about USD 5.06 billion, because most patients take oral therapy for months at home. Hospital pharmacy takes 22.5% and online pharmacy 13.3%, the fastest-growing route for repeat neuropathic pain refills.

Hospital pharmacy matters for capsaicin patch applications, chemotherapy-induced peripheral neuropathy managed in oncology clinics, and inpatient initiation. Online pharmacy grows about 9.4% a year in our model as mail-order refills of generic pregabalin and duloxetine spread. Scheduling rules limit how far controlled gabapentinoids move online in the United Kingdom, so the neuropathic pain channel mix there stays more retail-heavy.

How do Schedule 3 controls and FDA approvals regulate neuropathic pain drugs?

Neuropathic pain prescribing answers to 2 rule sets: controlled-drug scheduling of gabapentinoids, and regulator approval of new non-opioid mechanisms. Douglas Insights counts 2 regulatory milestones that move the model: UK scheduling of gabapentinoids, worth 0.31 points of lost volume, and the FDA approval of a sodium-channel pain drug.

The Home Office placed pregabalin and gabapentin in Schedule 3 of the Misuse of Drugs Regulations 2001 from 1 April 2019, with a 28-day prescription validity. These controls protect against misuse but add friction to every refill of neuropathic pain therapy.

The United States Food and Drug Administration approved Journavx (suzetrigine) 50 mg tablets for moderate to severe acute pain in adults on 30 January 2025. Journavx is a non-opioid that targets a sodium-channel pain-signalling pathway in peripheral nerves. The approval covered acute pain only, based on 874 participants in pooled controlled trials and 256 in an open-label study. Any neuropathic pain label needs its own Phase 3 evidence, which is why the DPN programme matters so much.

Which late-stage neuropathic pain molecules reach diabetic patients before 2030?

Three molecules lead the late-stage neuropathic pain pipeline: suzetrigine in two Phase 3 DPN studies, VX-993 in Phase 2, and pilavapadin heading into Phase 3. Douglas Insights expects the first sodium-channel DPN label in 2028 at the earliest.

Lexicon reported topline results from its 496-patient Phase 2b PROGRESS study of pilavapadin in diabetic peripheral neuropathic pain on 3 March 2025. The 10 mg arm cut average daily pain scores by 1.74 points against 1.31 for placebo, and Lexicon chose that dose for Phase 3. Pilavapadin inhibits adaptor-associated kinase 1 (AAK1) and avoids opioid pathways.

Vertex keeps enrolling and dosing patients in its VX-993 Phase 2 DPN study alongside the suzetrigine Phase 3 pair. If enrollment completes by end-2026, readouts follow in 2027 and a filing after that. In our model each year of delay pushes about USD 0.44 billion of 2035 neuropathic pain value out of the forecast window.

What if suzetrigine wins a DPN label early: how far does the neuropathic pain forecast move by 2035?

The neuropathic pain base case reaches USD 13.8 billion in 2035; a slower path ends at USD 11.5 billion and a faster one at USD 16.3 billion. The spread rests on DPN approval timing and how quickly generics erode branded prices.

The base case uses 3.12% volume and 2.57% price, giving 5.77% a year. The slower case cuts volume to 2.2% and price to 1.6%, a 3.84% rate, if suzetrigine misses in DPN and scheduling spreads. The faster case lifts volume to 3.9% and price to 3.5%, a 7.54% rate, if Vertex completes enrollment by end-2026 as guided and wins a broad peripheral neuropathic pain label.

Sensitivity is steep. Timing matters most. One extra point of annual patient growth adds about USD 1.40 billion to the 2035 total. Published neuropathic pain forecasts span about 4.10% to 8.35% a year; our 5.77% sits in the lower half because generic pressure on gabapentinoids is modelled explicitly.

Douglas Exclusive: the neuropathic pain catalyst calendar

The neuropathic pain catalyst calendar is a Douglas Insights model built from 16 inputs: 9 dated events from regulators and companies, and 7 company or epidemiology disclosures. Each dated event carries the 2035 value our model ties to it. The finding: 38.3% of the USD 5.93 billion value gain from 2025 to 2035 depends on sodium-channel and novel agents.

The calendar counts when each catalyst lands and how much neuropathic pain value it moves. Five of the 9 events have already happened, 2 rest on company guidance and 2 are modelled. The 2027 readouts carry the most weight, because they decide whether the sodium-channel segment grows 18.75% a year or stalls near its 2025 base.

Which methodology rebuilds USD 7.88 billion from 46.82 million neuropathic pain patient-years?

The model multiplies 46.82 million treated patient-years by USD 168.3 average net drug cost to reach USD 7.88 billion for neuropathic pain in 2025. It then compounds 3.12% volume and 2.57% price for 10 years to reach USD 13.8 billion.

The build covers 5 regions and 31 country rows, 6 drug classes, 5 named indications and 3 channels, with 16 calendar inputs. Region rows sum to the global total in 2025 and 2035 within USD 0.1 million. Segment 2035 values add to USD 13.8 billion exactly.

The sums hold. Cross-checks agree closely. Our 2025 figure sits 4.6% and 8.3% below published global estimates of USD 8.26 billion and USD 8.59 billion, because we exclude devices and over-the-counter products. Viatris Lyrica sales equal 16.0% of our anticonvulsant segment, consistent with a mostly generic class.

Sources

1. Vertex Pharmaceuticals Pipeline and business update, suzetrigine DPN Phase 3 (2026)
2. US Food and Drug Administration FDA approves novel non-opioid treatment for moderate to severe acute pain (2025)
3. Viatris Fourth-quarter and full-year 2025 financial results (2026)
4. UK Government Reclassification of pregabalin and gabapentin to Schedule 3 (2019)
5. National Institute of Neurological Disorders and Stroke Peripheral neuropathy fact sheet (2025)
6. Lexicon Pharmaceuticals Pilavapadin Phase 2b PROGRESS topline results (2025)
7. Collegium Pharmaceutical Fourth quarter and full-year 2025 financial results (2026)
8. Grünenthal 2025 full year result (2026)